Glycine

Glycine

SCHEMBL6795033

Cc1ccc(S(=O)(=O)OCc2ccccc2)cc1.NCC(=O)O

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D

The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
MAPT P10636 2/20 0.48
CA1 P00915 6/20 0.47
CA2 P00918 6/20 0.47
CA9 Q16790 3/20 0.47
AR P10275 1/20 0.44
STAT3 P40763 1/20 0.44
KEAP1 Q14145 1/20 0.44
NFE2L2 Q16236 1/20 0.44
KMT2A Q03164 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
BCHE P06276 1/20 0.43
ACHE P22303 1/20 0.43
CA12 O43570 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
GAA P10253 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Beta-Alanine SCHEMBL28276772 0.92 LMNA (0.52) LMNAMAPTCA1CA2CA9
SCHEMBL2890 0.89 CA9 (0.53) LMNAMAPTCA1CA2CA9
Ammonia Solution, Strong SCHEMBL9470841 0.88 CA9 (0.51) LMNAMAPTCA1CA2CA9
Toluene SCHEMBL9257721 0.88 CA9 (0.51) LMNAMAPTCA1CA2CA9
Alanine SCHEMBL27541536 0.86 LMNA (0.49) LMNAMAPTCA1CA2CA9
D-Alanine SCHEMBL21580302 0.86 LMNA (0.49) LMNAMAPTCA1CA2CA9
Alanine SCHEMBL21580304 0.86 LMNA (0.49) LMNAMAPTCA1CA2CA9
SCHEMBL16213019 0.85 LMNA (0.48) LMNAMAPTCA1CA2CA9
1-Aminocyclopropane Carboxylic Acid SCHEMBL27560063 0.84 LMNA (0.47) LMNAMAPTCA1CA2CA9
Phenylalanine SCHEMBL7396105 0.83 SLC7A5 (0.55) LMNAMAPTCA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119368011-A Polyamide composite film 万华化学集团股份有限公司 2025-01-28 CN disclosed
CN-222263523-U Perovskite solar cell 旗滨新能源发展(深圳)有限责任公司 2024-12-27 CN disclosed
CN-115968113-A Method for manufacturing structure with conductive pattern, kit and system 旭化成株式会社 2023-04-14 CN disclosed
US-20220127605-A1 NUCLEIC ACID CONJUGATE KYOWA KIRIN CO., LTD. (JP) 2022-04-28 US disclosed
EP-3888663-A1 NUCLEIC ACID COMPLEX Kyowa Kirin Co., Ltd. (JP) 2021-10-06 EP disclosed
WO-2021027306-A1 DIHYDROARTEMISININ-STEROID CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF 云白药征武科技(上海)有限公司 2021-02-18 WO disclosed
EP-3409780-B1 NUCLEIC ACID COMPLEX KYOWA KIRIN CO LTD (JP) 2021-01-20 EP disclosed
US-10745700-B2 Nucleic acid conjugate KYOWA KIRIN CO., LTD. (JP) 2020-08-18 US disclosed
CN-110678174-A Prodrugs of treprostinil 联合治疗学有限公司 2020-01-10 CN disclosed
US-20190055558-A1 NUCLEIC ACID CONJUGATE KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-02-21 US disclosed
EP-3409780-A1 NUCLEIC ACID COMPLEX Kyowa Hakko Kirin Co., Ltd. (JP) 2018-12-05 EP disclosed
US-6835851-B2 Reacting said alpha - substituted acrylic acid with an chloro acid so as to obtain an acid chloride, now reacting acid chloride thus obtained with an amino ester in presence of an organic base, to acheive coupling BIOPROJET (FR) 2004-12-28 US disclosed
CN-1165336-C Peptide, a method of obtaining it and a pharmaceutical compound based on it ��ķ����ŵ 2004-09-08 CN disclosed
US-20020055645-A1 Process for synthesizing N-(mercaptoacyl) amino acid derivatives from alpha-substituted acrylic acids BIOPROJET (FR) 2002-05-09 US disclosed
CN-1159758-A Peptides, methods for obtaining and derivatizing peptides and pharmaceutical compositions based on derivatised peptides V I DEIGIN (RU) 1997-09-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220127605-A1 NUCLEIC ACID CONJUGATE NSUN3, NSUN2, RNASEH1 LMNA 1097/4885MAPT 3449/4885CA1 827/4885
US-10745700-B2 Nucleic acid conjugate SLC29A1, NSUN2, H1-2 LMNA 601/4885MAPT 2840/4885CA1 607/4885
US-20020055645-A1 Process for synthesizing N-(mercaptoacyl) amino acid derivatives from alpha-substituted acrylic acids TST, ASS1, SULT1A1 LMNA 4652/4885MAPT 4554/4885CA1 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.